A comprehensive understanding of these pathways and their interplay with GLP1R is pivotal for identifying novel therapeutic targets and for devising strategies with potential clinical applications in diverse cardiovascular diseases, particularly DCM. This evidence concerns the gene GLP1R and familial dilated cardiomyopathy.